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Abstract
Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular (CV) disease; however, conclusive
evidence that glycemic control leads to improved cardiovascular outcomes is lacking. Saxagliptin is a potent,
selective dipeptidyl peptidase-4 inhibitor approved as an adjunct to diet and exercise to improve glycemic control
in adults with T2DM. Saxagliptin was evaluated in a series of phase III trials as monotherapy; add-on therapy to
metformin, a sulfonylurea, or a thiazolidinedione; and as initial therapy in combination with metformin. Saxagliptin
consistently improved glycemic control (as reflected by significant decreases in glycated hemoglobin, fasting
plasma glucose, and postprandial glucose compared with controls) and was generally well tolerated. In these
analyses, saxagliptin had clinically neutral effects on body weight, blood pressure, lipid levels, and other markers of
CV risk compared with controls. A retrospective meta-analysis of 8 phase II and phase III trials found no evidence
that saxagliptin increases CV risk in patients with T2DM (Cox proportional hazard ratio, 0.43; 95% CI, 0.23-0.80 for
major adverse cardiovascular events retrospectively adjudicated). Instead, it raised the hypothesis that saxagliptin
may reduce the risk of major adverse CV events. A long-term CV outcome trial, Saxagliptin Assessment of Vascular
Outcomes Recorded in Patients with Diabetes Mellitus-THrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) is
currently ongoing to determine whether saxagliptin reduces CV risk in T2DM.
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Introduction
It is well established that patients with type 2 diabetes mel-
litus (T2DM) are at increased risk of cardiovascular (CV)
disease [1,2]. In addition to the chronic elevations in
plasma glucose that contribute to increased CV risk [3,4],
patients with T2DM often have comorbid conditions–
such as obesity, hypertension, and dyslipidemia–that
further contribute to the development of CV complica-
tions. As an example, the National Health and Nutrition
Examination Survey (1999-2002) [5] revealed that patients
with diabetes had mean body mass index (BMI) of 31.8
kg/m
2, more than half reported having hypertension, and
more than one third had dyslipidemia. Epidemiologic stu-
dies have shown a relationship between increasing levels
of glycated hemoglobin (HbA1c) or fasting plasma glucose
levels and the increased risk of CV complications, includ-
ing coronary heart disease, chronic heart failure, and
stroke; an association has also been shown between HbA1c
levels and all-cause mortality [3,4].
Despite these epidemiologic findings, evidence for the
benefit of improved glycemic control on CV events and
mortality in patients with T2DM remains mixed. The 10
years of primary follow-up from the landmark UK Pro-
spective Diabetes Study (UKPDS) [6] and 3 recent out-
come studies (the Action to Control Cardiovascular Risk
in Diabetes [ACCORD], Action in Diabetes and Vascular
Disease: Preterax and Diamicron Modified Release Con-
trolled Evaluation [ADVANCE] and Veterans Affairs Dia-
betes Trial [VADT]) all individually failed to demonstrate
that intensive glycemic control reduces CV events and
mortality. However, a subsequent meta-analysis increased
the statistical power of these studies by combining them
with the results of the PROactive trial [7] and was able to
show that intensive glycemic control significantly reduces
coronary events compared with standard glycemic control,
without an increased risk of death [8]. Moreover, an addi-
tional 10-year follow-up from the UKPDS demonstrated a
benefit of intensive glycemic control on the risk of
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stroke or peripheral vascular disease [9].
In addition to conflicting data regarding the impact of
intensive glycemic control on CV disease risk among
patients with T2DM, the CV safety of the thiazolidine-
diones (particularly rosiglitazone) has come into question,
ultimately leading the US Food and Drug Administration
(FDA) to place severe restrictions on its use. The increased
scrutiny also led the FDA to issue guidance recommenda-
tions in December 2008, requiring that all investigational
antidiabetic agents demonstrate that treatment will not
result in an unacceptable increase in CV risk, via meta-
analysis of phase II and III trial data and/or large, long-
term CV safety studies [10]. Although agents approved
before these recommendations were not subject to this
requirement, the CV safety of recently approved therapies
(even those with studies designed before the 2008 gui-
dance) has been carefully reviewed using the overall rela-
tive risk criteria defined by the FDA.
The current article reviews the CV safety of the selective
dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin,
beginning with a brief overview of the rationale for use of
this class of agents in T2DM. Phase III clinical trial data
regarding CV risk factors are discussed, followed by the
results of a meta-analysis of pooled data from phase II and
phase III trials, conducted in accordance with the FDA
guidance. The results of similar studies with other cur-
rently available DPP-4 inhibitors are summarized, as are
the ongoing clinical trials to determine the impact of treat-
ment with this class of agents on CV outcomes in patients
with T2DM.
Dipeptidyl Peptidase-4 Inhibitors: Rationale for Use
Dipeptidyl peptidase-4 is the enzyme that rapidly deacti-
vates glucagon-like peptide-1 (GLP-1) and glucose-depen-
dent insulinotropic polypeptide [11,12]; these incretin
hormones, secreted from the gut in response to food
intake, decrease postprandial glucose levels by stimulating
insulin secretion, inhibiting glucagon secretion, and at
pharmacologic concentrations, delaying gastric emptying
[11,13]. Because the glycemic effects of DPP-4 inhibitors
are glucose dependent and decline as postprandial serum
glucose levels return to normal ranges, they are less likely
to cause hypoglycemia. Consistent with this idea, low fre-
quencies of hypoglycemic events have been observed dur-
ing clinical use of DPP-4 inhibitors [14-19]. Moreover,
these orally administered agents have demonstrated bene-
ficial effects on pancreatic b-cell function [20-22].
Compared with other antihyperglycemic agents, DPP-4
inhibitors are associated with lower risks of hypoglycemia
and weight gain than the sulfonylureas (SUs), lower risk
of edema and chronic heart failure than the thiazolidine-
dione (TZDs), lower risk of diarrhea or gastrointestinal
intolerance than metformin, and associated with fewer
gastrointestinal adverse events than GLP-1 agonists
[14-19]. Finally, as discussed in the next section, treat-
ment with DPP-4 inhibitors has not been associated with
increased CV risk [23-25]. The most frequently reported
adverse reactions associated with DPP-4 inhibitors
include headache, nasopharyngitis, and urinary tract and
upper respiratory infections [26]. There have been spon-
taneous reports of pancreatitis among patients receiving
DPP-4 inhibitors, including saxagliptin; however, there
have been no increases in the incidence of pancreatitis
events among DPP-4 inhibito r sv e r s u sc o m p a r a t o r si n
the pooled clinical experience of either saxagliptin, sita-
gliptin, [27] or vildagliptin [28]. Furthermore, 2 epide-
miologic assessments of sitagliptin have failed to show an
increase in pancreatitis events [29,30]. A clinical and
scientific review of the evidence on DPP-4 inhibitors and
pancreatitis calls for additional data [31]. In this setting
of uncertainty, the US saxagliptin label calls for disconti-
nuation of treatment for events of pancreatitis.
Effects of Saxagliptin on Markers of Cardiovascular Risk
The core saxagliptin phase III trial program consisted of
6 multicenter, randomized, double-blind, 24-week studies
that assessed the efficacy and safety of saxagliptin 2.5, 5,
and 10 mg versus placebo as monotherapy in drug-naive
patients [17,32]; saxagliptin 2.5, 5, and 10 mg versus pla-
cebo as add-on to metformin [18], saxagliptin 2.5 and 5
mg versus placebo as add-on to a TZD [15], or an SU
(glyburide) [14]; and saxagliptin 5 and 10 mg as initial
combination therapy with metformin versus metformin
monotherapy in drug-naive patients [19]. In all of these
studies, saxagliptin consistently improved glycemic con-
trol in patients with T2DM, as reflected by significant
reductions in HbA1c, fasting plasma glucose, and post-
prandial glucose, as well as by the greater percentages of
patients achieving the American Diabetes Association-
recommended target HbA1c (< 7%) compared with con-
trols. In addition, saxagliptin was generally well tolerated,
with a low risk of hypoglycemia or weight gain. The 10-
mg dose included in the phase III trials offered no effi-
cacy benefit over the 5 mg dose and is therefore not an
FDA-approved dose, despite an acceptable safety profile
and no evidence of dose-limiting toxicity.
A pooled analysis of data from the phase III trials was
conducted to assess the effects of saxagliptin on markers
of CV risk. Blood pressure (multiple seated measure-
ments), body weight, and lipid levels were routinely mea-
sured at multiple study visits. Descriptive statistics were
summarized using observed values for blood pressure
and last observation carried forward (LOCF) methods for
lipid levels and body weight. Forest plots showing the
point estimates and 95% CIs for the changes in these
parameters with saxagliptin 5 mg and corresponding
comparator groups are presented in Figures 1, 2 & 3.
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reduced in the saxagliptin and control groups, and there
were no clinically meaningful differences across groups
(Figure 1). Changes in lipid parameters in the saxagliptin
treatment groups generally paralleled the changes
observed in the corresponding control groups (Figure 2).
Low-density lipoprotein (LDL) showed small increases
from baseline with saxagliptin 5 mg (and with placebo) in
4 clinical trials, no change in 1 trial, and a small decrease
from baseline in 1 trial [33]. Small increases from base-
line in high-density lipoprotein (HDL) were seen with
saxagliptin monotherapy and with initial combination
therapy with saxagliptin plus metformin, as well as in the
corresponding control groups. Across the 3 studies of
saxagliptin as add-on therapy, changes in HDL varied.
Mean changes in triglycerides varied across all 6 studies,
Figure 1 Mean changes from baseline to 24 weeks in systolic and diastolic blood pressure [23]. Forest plot shows the point estimate and
95% CI in the SAXA 5-mg and control groups. DBP = diastolic blood pressure; MET = metformin; PBO = placebo; SAXA = saxagliptin; SBP =
systolic blood pressure; ST = short term; SU = sulfonylurea; TZD = thiazolidinedione.
Figure 2 Mean change from baseline to 24 weeks in LDL cholesterol, HDL cholesterol, and triglycerides [23]. Forest plot shows the point
estimate and 95% CI in the SAXA 5-mg and control groups. Measurements of each lipid parameter were not available for all patients; therefore,
the number of patients (n) is presented as a range. HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol;
MET = metformin; PBO = placebo; SAXA = saxagliptin; ST = short term; SU = sulfonylurea; TG = triglycerides; TZD = thiazolidinedione.
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within each trial [33].
Saxagliptin exhibited weight-neutral effects across the
phase III clinical trials (Figure 3). At the 5-mg dose, mean
body weight declined slightly from baseline in 3 trials, was
essentially unchanged in 2 trials, and increased slightly in
the trial of add-on to TZD (which may reflect, at least in
part, the weight effects of the TZD). Similar small changes
in body weight were seen with saxagliptin 2.5 mg (data
not shown) [33].
The Current Regulatory Environment for the Approval of
Antidiabetic Agents
US Food and Drug Administration Guidance for
Cardiovascular Safety
In December 2008, the FDA issued recommendations to
provide meaningful data for estimating the CV risk asso-
ciated with newer antidiabetic drugs [10]. This guidance
recognizes that although improved long-term glycemic
control measured by HbA1c leads to reduced risk of
microvascular complications and remains an acceptable
primary efficacy endpoint, T2DM is also associated with
increased risk of CV disease–the primary cause of mor-
bidity and mortality in T2DM patients.
To establish the safety of investigational antidiabetic
medications, the FDA guidance calls for a systematic
analysis (incorporating blinded adjudication) of CV
death, myocardial infarction, and stroke using pooled
data from phase II and phase III clinical trials, which
should be designed to facilitate meta-analysis [10]. The
relative risk ratio and its 2-sided 95% CI should be gen-
erated by comparing the number of CV events occurring
in patients treated with the new drug versus those
receiving control treatments. For an investigational anti-
diabetic drug to be considered for FDA approval, the
results of this analysis must demonstrate that the upper
bound of the 95% CI is < 1.8. If the overall risk-benefit
analysis supports approval and the upper bound of the
95% CI is in the range of 1.3 to 1.8, a postmarketing CV
safety trial will be necessary to document that the upper
bound of the 95% CI is < 1.3. If the data available at the
time of the new drug application show that the upper
bound is < 1.3, a postmarketing CV safety trial may not
be necessary [10].
Saxagliptin Meta-analysis
Although the saxagliptin trials intended for registration
completed their primary analysis point before the 2008
FDA guidance, an assessment of investigator-identified
CV events was completed in a meta-analysis of pooled
data from 8 phase II and phase III clinical trials [23].
These trials involved a total of 3356 patients who
received saxagliptin at doses ranging from 2.5 mg to 100
mg and 1251 patients who received a control treatment
(placebo, metformin, uptitrated glyburide, or a TZD).
Methods
Cardiovascular events (death, myocardial infarction,
stroke, and cardiac ischemic events) reported by investiga-
tors were systematically identified using a list of Medical
Figure 3 Mean change from baseline to 24 weeks in body weight [23]. Forest plot showing point estimate and 95% CI of the in the SAXA
5-mg and control groups. MET = metformin; PBO = placebo; SAXA = saxagliptin; ST = short term; TZD = thiazolidinedione; SU = sulfonylurea.
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term diagnoses; all identified potential CV events subse-
quently went through independent adjudication by 2 inde-
pendent reviewers. Patients in the saxagliptin groups were
compared with those in the comparator groups; full CV
event identification and statistical methods for this analysis
have previously been published [23].
To obtain exposure-adjusted incidence rates for CV
events in the meta-analysis of pooled data (and in accor-
dance with the FDA guidance), the number of patients in
each treatment group was divided by the number of
patient-years of exposure, excluding exposure after the first
event. The rates were presented per 1000 patient-years to
adjust for exposure imbalances across treatment groups.
Results
Within each trial and across all trials, the saxagliptin and
comparator groups were generally balanced for baseline
demographic and clinical characteristics, including median
age (54 y vs 55 y), sex (51% vs 50% female), race (73% vs
71% white), mean BMI (30.4 kg/m
2 vs 30.3 kg/m
2), mean
HbA1c (8.5% vs 8.4%), and presence of at least 1 additional
CV risk factor other than T2DM (81% vs 83%; including
hypertension [52% vs 55%], hypercholesterolemia [44% vs
45%], and history of CV disease [12% vs 13%]).
The meta-analysis identified a total of 41 first major
a d v e r s eC Ve v e n t s( M A C E ) ,i n c l u d i n gC V - r e l a t e dd e a t h ,
nonfatal myocardial infarction, and nonfatal stroke. These
events occurred in 23 patients who received saxagliptin
(0.7% of all saxagliptin-treated patients) and 18 patients
who received comparators (1.4% of all comparator-treated
patients) (Table 1). In addition, an independent clinical
events committee performed a blinded, post-hoc,
retrospective adjudication of all deaths and all events pos-
sibly representing a myocardial infarction and/or stroke
from among all events coded to any of the 148 preferred
terms representing possible ischemic events from 2 Med-
DRA standard queries: “myocardial infarction” and “cen-
tral nervous system hemorrhages and cerebrovascular
accidents” [23]. The results were close to the numbers of
investigator-reported MACE (Table 1). From a total of
147 cases reviewed for potential MACE, 40 patients had
confirmed events, including 22 saxagliptin-treated patients
and 18 comparator-treated patients. Investigator reports
and the independent clinical events committee identified
38 common patients with MACE; 3 patients were unique
to the investigator report and 2 patients were unique to
the adjudicated cases.
In the analysis of relative risk with saxagliptin, the Cox
proportional hazard ratio was 0.44 (95% CI, 0.24-0.82)
for investigator-based assessments and 0.43 (95% CI,
0.23-0.80) for independently adjudicated events [23].
The numbers of patients with a CV event per 1000
patient-years of follow-up are lower with all saxagliptin
regimens combined than with all comparators (Table 2).
This finding suggested that saxagliptin may reduce CV
risk in patients with T2DM, a hypothesis that will be
evaluated in the Saxagliptin Assessment of Vascular
Outcomes Recorded in Patients with Diabetes Mellitus-
Thrombolysis in Myocardial Infarction 53 (SAVOR-
TIMI 53) trial [34].
Cardiovascular Risk With Other Dipeptidyl Peptidase-4
Inhibitors
Pooled analyses of nonadjudicated events with sitagliptin
and adjudicated CV-related events with vildagliptin,
Table 1 Retrospective Analysis of CV Events With Saxagliptin Versus Comparators in Phase II/III Clinical Trials [23]
Number of Patients (%)
SAXA
2.5 mg
(n = 937)
SAXA
5m g
(n = 1269)
SAXA
10 mg
(n = 1000)
All SAXA*
(n = 3356)
Controls
(n = 1251)
Hazard Ratio
(95% CI)
†
Investigator-reported MACE 6 (0.6) 6 (0.5) 11 (1.1) 23 (0.7) 18 (1.4) 0.44
(0.2-0.82)
Adjudicated MACE 6 (0.6) 7 (0.6) 9 (0.9) 22 (0.7) 18 (1.4) 0.42
(0.23-0.80)
Myocardial infarction
‡
Stroke
‡
Other CV deaths
§
2 (0.2)
4 (0.4)
0 (0)
4 (0.3)
4 (0.3)
0 (0)
2 (0.2)
3 (0.3)
4 (0.4)
8 (0.2)
11 (0.3)
4 (0.1)
8 (0.6)
5 (0.4)
6 (0.5)
All deaths 3 (0.3) 3 (0.2) 4 (0.4) 10 (0.3) 12 (1.0)
CV deaths
|| 1 (0.1) 2 (0.2) 4 (0.4) 7 (0.2) 10 (0.8)
CV = cardiovascular; MACE = major adverse cardiovascular event; SAXA = saxagliptin.
*Includes 150 patients who received saxagliptin 20, 40, and 100 mg daily in a dose-ranging trial.
†Cox proportional hazard ratio (95% CI) for all saxagliptin vs controls.
‡Includes patients with fatal and nonfatal events; patients with a myocardial infarction and stroke were counted in each category.
§CV deaths that could not be clearly determined as myocardial infarction or stroke.
||Investigator-reported and committee-adjudicated CV death rates were identical.
Table reprinted from Postgraduate Medicine, (3)122, Frederich R, Alexander JH, Fiedorek FT et al. A Systematic Assessment of Cardiovascular Outcomes in the
Saxagliptin Drug Development Program for Type 2 Diabetes, page 20. Copyright 2010, with permission from JTE Multimedia.
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tive risk for sitagliptin versus comparators was 0.68
(95% CI, 0.41-1.12) [24]. With vildagliptin, relative risks
of cardiocerebrovascular events were 0.88 (95% CI, 0.37-
2.11) with vildagliptin 50 mg once daily and 0.84 (95%
CI, 0.62-1.14) with vildagliptin 50 mg twice daily [25].
Data from a prespecified, prospective meta-analysis of
the linagliptin phase III studies showed a relative risk of
CV-related events with linagliptin versus comparators of
0.34 (95% CI, 0.16-0.70) [35]. Meta-analysis of phase II
and III studies with alogliptin versus placebo calculated
a relative risk of 0.63 (95% CI, 0.21-1.91) [36].
Ongoing Cardiovascular Outcome Studies
Saxagliptin is being evaluated in the SAVOR-TIMI 53 trial
(ClinicalTrials.gov identifier NCT01107886) [34], to
demonstrate CV safety. Additionally, based on the results
of the saxagliptin meta-analysis, the SAVOR-TIMI 53 trial
was also powered to determine whether saxagliptin can
reduce the risk of CV events. The study plans to enroll
16,500 patients with T2DM who have HbA1c ≥6.5% and a
high risk for CV events (defined as established CV disease
and/or multiple risk factors). Eligible patients will be ran-
domly allocated to receive saxagliptin (5 mg for patients
with normal or mildly impaired renal function or 2.5 mg
for those with moderate renal impairment) or placebo
once daily during the approximately 5-year study period,
the projected timeframe necessary to observe 1,040
MACE. The primary outcome is a composite of CV death,
nonfatal myocardial infarction, or nonfatal ischemic
stroke; completion is expected by the middle of 2015.
Sitagliptin is being evaluated in the TECOS trial (Rando-
mized, Placebo-Controlled Clinical Trial to Evaluate Car-
diovascular Outcomes After Treatment With Sitagliptin in
Patients With T2DM and Inadequate Glycemic Control
trial [NCT00790205]) [37], which is designed to assess CV
outcomes with sitagliptin (100 mg once daily; or 50 mg for
those with moderate renal impairment) versus placebo in
patients older than 50 years with preexisting CV disease
and HbA1c of 6.5% to 8.0% receiving usual care including
other antihyperglycemic agents. The primary outcome
measure is time to first CV event (a composite of CV
death, nonfatal myocardial infarction, nonfatal stroke, or
unstable angina requiring hospitalization). The study plans
to enroll 14,000 patients who will be treated and followed
up for ≤5 years, until 1300 CV events are observed; study
completion is expected in December 2014 [38].
Linagliptin, the newest DPP-4 inhibitor (approved by the
FDA in May 2011), will be evaluated for CV outcomes in
the CAROLINA trial (Multicentre, International, Rando-
mised, Parallel-Group, Double-Blind Study to Evaluate
Cardiovascular Safety of Linagliptin Versus Glimepiride in
Patients With Type 2 Diabetes Mellitus at High Cardio-
vascular Risk [NCT01243424]) [39]. The planned study
population is 6000 patients with T2DM who have preex-
isting or T2DM-related CV disease, are older than 70
years, or have ≥2 specified CV risk factors. The primary
endpoint is time to first occurrence of CV death, nonfatal
myocardial infarction, nonfatal stroke, or hospitalization
for unstable angina pectoris; study completion is expected
in 2018.
The effect of alogliptin on CV outcomes is being investi-
gated in patients with T2DM who have acute coronary
syndrome in the EXAMINE trial (Examination of Cardio-
vascular Outcomes: Alogliptin vs Standard-of-Care in
Patients With T2DM and Acute Coronary Syndrome trial
[NCT00968708]) [40]. This study plans to enroll 5400
patients (HbA1c 6.5%-11.0% on monotherapy or combina-
tion antidiabetic therapy, or 7.0%-9.0% if the regimen
includes insulin) who have a diagnosis of acute coronary
syndrome within 15 to 90 days before randomization.
Patients will be randomly allocated to receive alogliptin or
placebo once daily for up to 4.75 years, each in addition to
the standard of care; the daily dose of alogliptin will be
25 mg for patients with normal or mildly impaired renal
function, 12.5 mg for those with moderate renal impair-
ment, and 6.25 mg for those with severe renal impairment
or end-stage renal disease. The primary outcome is a com-
posite of CV death, nonfatal myocardial infarction, nonfa-
tal stroke, and urgent revascularization due to unstable
angina, with study completion expected in 2014.
Conclusion
Recent concerns regarding CV safety have been raised
by data from various studies of traditional diabetes treat-
ment regimens [41], rosiglitazone [42], and SUs [43,44];
thus, attention has focused on the CV safety of all
Table 2 CV Event Rate (Incidence [SD]) per 1000 Patient-
Years [47]
All Saxagliptin*
(n = 3356)
Controls
(n = 1251)
Standard MedDRA query MACE
† 28.4 (2.9) 31.9 (5.0)
Acute CV events 10.7 (1.8) 17.6 (3.7)
Custom MACE
‡ 6.2 (1.3) 13.1 (3.2)
Primary MACE
§ 6.2 (1.3) 13.9 (3.3)
CV = cardiovascular; MACE = major adverse cardiovascular event; MedDRA =
Medical Dictionary for Regulatory Activities.
*Includes 150 patients who received saxagliptin 20, 40, and 100 mg daily in a
dose-ranging trial.
†Standard MedDRA query MACE is a composite endpoint of
CV death and all standard MedDRA query preferred terms for “myocardial
infarction” and “central nervous system hemorrhages and cerebrovascular
accidents.”
‡Custom MACE is a composite endpoint of CV death, MI and stroke using
MedDRA preferred terms indicative of MACE suggested by the FDA.
§Primary MACE includes adverse events of myocardial infarction, stroke, or CV
death developed by the sponsor. In practice, custom MACE differed from
primary MACE only by a single subject which the investigator updated to an
event of anterior MI. Such an update was allowed by the sponsor rules.
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trials of the DPP-4 inhibitor saxagliptin as monotherapy,
add-on therapy, or initial combination therapy with met-
formin showed that saxagliptin does not adversely affect
blood pressure, lipid levels, body weight, or other CV
markers compared with control treatments.
In accordance with the FDA guidance for establishing
the CV safety of new antidiabetic drugs, a retrospective
meta-analysis was conducted using pooled data from the
saxagliptin phase II and phase III clinical trials. The
meta-analysis found no evidence that saxagliptin
increases CV risk in patients with T2DM, and a long-
term outcome study (SAVOR-TIMI 53) is currently
ongoing to test the hypothesis that saxagliptin treatment
m a ye v e nr e d u c eC Vr i s k[ 3 4 ] .M e t a - a n a l y s e so fo t h e r
DPP-4 inhibitors [37,39,40,45,46] have also failed to
detect an increased CV risk associated with this drug
class; outcome studies in patients at high risk for CV
events are also underway for sitagliptin, alogliptin, and
linagliptin [37,39,40,45,46]. Thus, a substantial body of
data supporting the CV safety of DPP-4 inhibitors has
already been generated, and in the next few years, an
unprecedented amount of clinical outcome data for sax-
agliptin and other DPP-4 inhibitors will address the con-
cerns and possible benefits of DPP-4 inhibitors in
diabetes-associated CV disease.
In conclusion, the incretin medication class is cur-
rently approved as monotherapy or combination therapy
in adults with T2DM and has been shown to be benefi-
cial in glucose management and the achievement of
HbA1c goals. Although early analyses on CV safety and
possible benefits are promising, definitive data have not
yet been generated. Future and ongoing CV morbidity
and mortality studies across the DPP-4 inhibitor drug
class will offer more insight into the risks and rewards
of diabetes care and its associated outcomes.
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